Inovio Pharmaceuticals (NSDQ:INO) reported today that its synthetic HIV vaccine, Pennvax-GP, demonstrated durable antibody and T cell immune responses throughout a Phase I trial.
The company found that Pennvax-GP plasmids delivered intradermally with Inovio’s Cellectra device triggered equivalent or superior immune responses in healthy volunteers compared to intramuscular delivery of the plasmids using the same device.
Get the full story at our sister site, Drug Delivery Business News.
The post Inovio touts intradermal delivery of HIV vaccine appeared first on MassDevice.
from MassDevice https://ift.tt/2PoE17L
Cap comentari:
Publica un comentari a l'entrada